martes, 2 de febrero de 2016

National Guideline Clearinghouse | Guidelines by Topic: Cardiovascular Diseases (10)

National Guideline Clearinghouse | Guidelines by Topic



National Guideline Clearinghouse (NGC)

Guidelines by Topic

Cardiovascular Diseases (393)
181-200 of 393   < Previous Next >
 
181. 
Lenalidomide in multiple myeloma. 2012 May 30. NGC:009789
Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]. View all guidelines by thedeveloper(s)
183. 
2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. 2012 Apr. NGC:009500
European Cardiac Arrhythmia Society - Disease Specific Society; European Heart Rhythm Association - Professional Association; Heart Rhythm Society - Professional Association. View all guidelines by the developer(s)
184. 
American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis. 2000 Mar-Apr (revised 2012 Mar-Apr). NGC:009162
American Association of Clinical Endocrinologists - Medical Specialty Society. View all guidelines by the developer(s)
185. 
Stem cell transplantation in multiple myeloma. 2012 Mar 29. NGC:009865
Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]. View all guidelines by thedeveloper(s)
186. 
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation. 2012 Mar. NGC:009077
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
187. 
Management of patients with refractory angina: Canadian Cardiovascular Society/Canadian Pain Society joint guidelines. 2012 Mar-Apr. NGC:009734
Canadian Cardiovascular Society - Professional Association; Canadian Pain Society - Professional Association. View all guidelines by the developer(s)
181-200 of 393   < Previous Next >

No hay comentarios:

Publicar un comentario